The French PH Network PULMOTENSION Investigators: Grégoire De La Villeon (Paediatric and Congenital Cardiology Department, M3C Regional Reference Centre, University Hospital, Montpellier, France; Paediatric Cardiology and Rehabilitation Unit, Saint-Pierre Institute, Palavas-Les-Flots, France), Stéphanie Douchin (Cardiopédiatrie, Hôpital Couple Enfant, CHU Grenoble Alpes, Grenoble, France), Xavier Iriart (Paediatric and Congenital Cardiology Department, M3C National Reference Centre, Bordeaux University Hospital, Bordeaux, France; IHU Liryc, Electrophysiology and Heart Modelling Institute, Bordeaux University Foundation, Pessac, France), Lauriane Le Gloan (Cardiologie Congénitale Adulte, Institut du Thorax, CHU Nantes, Nantes, France), Caroline Ovaert (Department of Pediatric Cardiology, La Timone Hospital, CHU Marseille, France), Martine Reynaud-Gaubert (Department of Respiratory Medicine and Lung Transplantation, AP-HM, Aix Marseille University, Hôpital Nord, Marseille, France), Sebastien Renard (Cardiology Department, AP-HM, La Timone Hospital, Marseille, France), Constance Vuillard (Department of Infectious Diseases, CHU Réunion, Saint-Pierre, Reunion, France).

Conflict of interest: H.J. Bogaard reports grants from Ferrer, MSD, Novartis, Dutch Cardiovascular Alliance and Janssen, and lecture honoraria from Janssen, outside the submitted work. L. Savale reports grants from Acceleron, AOP Orphan, Janssen, Merck and ShouTi, consulting fees from Acceleron, Bayer, Janssen and Merck, and lecture honoraria from Janssen and Merck, outside the submitted work. X. Jaïs reports grants from Acceleron, Janssen, MSD and Bayer Healthcare, lecture honoraria from Janssen and MSD, and travel support from MSD, outside the submitted work. L. Meijboom reports participation on an advisory board for Janssen, outside the submitted work. A. Chaouat reports consulting fees from Gossamer, lecture honoraria from Chiesi, travel support from AstraZeneca, MSD and J&J, outside the submitted work. V. Cottin reports consulting fees and lecture honoraria from Ferrer/United Therapeutics, outside the submitted work. C. Guignabert reports grants from Acceleron Pharma, MSD, Corterial pharmaceuticals, Structure Therapeutics (ex-ShouTi) and Janssen, and lecture honoraria from MSD, outside the submitted work. O. Sitbon reports grants from Acceleron (now MSD), AOP Orphan, Janssen (formerly Actelion) and MSD, consulting fees from Acceleron (now MSD), Altavant (now Enzyvant), AOP Orphan, Ferrer, Gossamer Bio, Janssen (formerly Actelion) and MSD, lecture honoraria from AOP Orphan, Janssen (formerly Actelion), Ferrer and MSD, and advisory board participation with Altavant (now Enzyvant), Gossamer Bio, Janssen (formerly Actelion) and MSD, outside the submitted work. D. Bonnet reports consulting fees from Janssen and Merck, and advisory board participation with Lupin, outside the submitted work. M. Humbert reports grants from Acceleron, AOP Orphan, Janssen, Merck and ShouTi, consulting fees from Acceleron, Aerovate, Altavant, AOP Orphan, Bayer, Chiesi, Ferrer, Janssen, Merck, MorphogenIX, ShouTi and United Therapeutics, lecture honoraria from Janssen and Merck, and advisory board participation with Acceleron, Altavant, Janssen, Merck and United Therapeutics, outside the submitted work. D. Montani reports grants from Acceleron, Janssen and Merck MSD, consulting fees from Acceleron, Janssen, Merck MSD and Ferrer, and lecture honoraria from Bayer, Janssen, Boehringer, Chiesi, GSK, Ferrer and Merck MSD, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose.